LRA-Genentech Award on Immune Resetting Therapies for Lupus

The LRA-Genentech Award on Immune Resetting Therapies for Lupus is a co-funded Lupus Research Alliance program with Genentech. It supports work on immune resetting therapies that are meant to be cost effective, reduce patient burden, and lower risk, so the award sits at the intersection of mechanistic research and therapy development. The program provides up to $150,000 per year and can support either one-year pilot projects on novel technologies or methodologies, or two-year mechanistic research projects. It is an annual United States grant program open to universities, nonprofit organizations, and research organizations, with individuals and for-profit companies excluded. The award range reaches $300,000 across a two-year project. The strongest applications will show a clear immune-resetting concept and a plausible mechanistic story for why the approach should work in lupus. Because the award is co-funded and development-oriented, the proposal needs to connect biology, practicality, and patient burden in a way that makes the next step feel both ambitious and credible.

Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.